Cited by 308Parkinson's Disease Mechanisms and TreatmentsGastrointestinal motility and disordersNuclear Receptors and Signaling

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease

Open access

Kelly, Leo P., Carvey, Paul M., Keshavarzian, Ali, Shannon, Kathleen M., Shaikh, Maliha, Bakay, Roy A. E., Kordower, Jeffrey H.·2014·Movement Disorders

DOI 10.1002/mds.25736PMC PMC4050039

Open this paper in CoChat — free account

Abstract

Parkinson's disease (PD) is a multifocal degenerative disorder for which there is no cure. The majority of cases are sporadic with unknown etiology. Recent data indicate that untreated patients with de novo PD have increased colonic permeability and that both de novo and premotor patients have pathological expression of α‐synuclein (α‐syn) in their colon. Both endpoints potentially can serve as disease biomarkers and even may initiate PD events through gut‐derived, lipopolysaccharide (LPS)‐induced neuronal injury. Animal models could be ideal for interrogating the potential role of the intestines in the pathogenesis of PD; however, few current animal models of PD encompass these nonmotor features. We sought to establish a progressive model of PD that includes the gastrointestinal (GI) dysfunction present in human patients. C57/BL6 mice were systemically administered one dose of either LPS (2.5 mg/kg) or saline and were sacrificed in monthly intervals (n = 5 mice for 5 months) to create a time‐course. Small and large intestinal permeability was assessed by analyzing the urinary output of orally ingested sugar probes through capillary column gas chromatography. α‐Syn expression was assessed by counting the number of mildly, moderately, and severely affected myenteric ganglia neurons throughout the GI tract, and the counts were validated by quantitative optical density measurements. Nigrostriatal integrity was assessed by tyrosine hydroxylase immunohistochemistry stereology and densitometry. LPS caused an immediate and progressive increase in α‐syn expression in the large intestine but not in the small intestine. Intestinal permeability of the whole gut (large and small intestines) progressively increased between months 2 and 4 after LPS administration but returned to baseline levels at month 5. Selective measurements demonstrated that intestinal permeability in the small intestine remained largely intact, suggesting that gut leakiness was predominately in the large intestine. Phosphorylated serine 129‐α‐syn was identified in a subset of colonic myenteric neurons at months 4 and 5. Although these changes were observed in the absence of nigrostriatal degeneration, an abrupt but insignificant increase in brainstem α‐syn was observed that paralleled the restoration of permeability. No changes were observed over time in controls. LPS, an endotoxin used to model PD, causes sequential increases in α‐syn immunoreactivity, intestinal permeability, and pathological α‐syn accumulation in the colon in a manner similar to that observed in patients with PD. These features are observed without nigrostriatal degeneration and incorporate PD features before the motor syndrome. This allows for the potential use of this model in testing neuroprotective and disease‐modifying therapies, including intestinal‐directed therapies to fortify intestinal barrier integrity. © 2013 International Parkinson and Movement Disorder Society

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1002/mds.25736

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
α-Synuclein in Lewy bodies
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144
Gastric α-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354
Gastrointestinal Dysfunction in Parkinson’s Disease
Fasano, A., Visanji, N. P., Liu, L. W. C., Lang, A. E., & Pfeiffer, R. F. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00007-1 · Cited by 1,016
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease
Forsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974
Self-citation
Gastrointestinal dysfunction in Parkinson's disease
Pfeiffer, R. F. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00307-7 · Cited by 933
Intestinal permeability: an overview
Bjarnason, I., Macpherson, A., & Hollander, D. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90708-4 · Cited by 927

Flagged first, then by citations

Show all 61 references

Research works printed but not linked: 2

Bing G, 1998, Microglia mediated dopaminergic cell death in the substantia nigra: a new animal model for Parkinson's disease [abstract], Neurosci Abstracts, 24, 44
10.1016/S1353-8020(11)70062-1 · DOI

Sorted by citations

Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Our gut microbiome: The evolving inner self
Kundu, P., Blacher, E., Elinav, E., & Pettersson, S. (2017) · Cell · doi:10.1016/j.cell.2017.11.024 · Cited by 633
Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naive Parkinson's disease patients
Bedarf, J. R., Hildebrand, F., Coelho, L. P., Sunagawa, S., Bahram, M., Goeser, F., Bork, P., & Wüllner, U. (2017) · Genome Medicine · doi:10.1186/s13073-017-0428-y · Cited by 642
The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis?
Houser, M. C., & Tansey, M. G. (2017) · npj Parkinson's Disease · doi:10.1038/s41531-016-0002-0 · Cited by 588
Brain-Gut-Microbiota Axis in Parkinson’s Disease
Mulak, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i37.10609 · Cited by 583
Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson's disease
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., Shibata, A., Fujisawa, Y., Minato, T., Okamoto, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142164 · Cited by 523
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Xu, D.-C., Yong, C., Xu, Y., Chen-Yu, S., & Peng, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 528
The endotoxin hypothesis of neurodegeneration
Brown, G. C. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1564-7 · Cited by 457
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic
Tan, A. H., Lim, S. Y., & Lang, A. E. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00681-2 · Cited by 392
Exploring Braak’s hypothesis of Parkinson’s disease
Rietdijk, C. D., Perez-Pardo, P., Garssen, J., van Wezel, R. J. A., & Kraneveld, A. D. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00037 · Cited by 395
Meta‐Analysis of Gut Dysbiosis in Parkinson's Disease
Nishiwaki, H., Ito, M., Ishida, T., Hamaguchi, T., Maeda, T., Kashihara, K., Tsuboi, Y., Ueyama, J., Shimamura, T., Mori, H., et al. (2020) · Movement Disorders · doi:10.1002/mds.28119 · Cited by 370
Role of Microbiota-Gut-Brain Axis in Regulating Dopaminergic Signaling
Hamamah, S., Aghazarian, A., Nazaryan, A., Hajnal, A. S., & Covașă, M. (2022) · Biomedicines · doi:10.3390/biomedicines10020436 · Cited by 327
A Role for Neuronal Alpha-Synuclein in Gastrointestinal Immunity
Stolzenberg, E. D., Berry, D. L., Yang, D., Lee, E. Y., Kroemer, A., Kaufman, S. S., Wong, G. C. L., Oppenheim, J. J., Sen, S., Fishbein, T., et al. (2017) · Journal of Innate Immunity · doi:10.1159/000477990 · Cited by 295
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?
Pellegrini, C., Antonioli, L., Colucci, R., Blandizzi, C., & Fornai, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1856-5 · Cited by 270
Gut microbiota in patients with Parkinson's disease in southern China
Lin, A., Zheng, W., He, Y., Tang, W., Wei, X., He, R., Huang, W., Su, Y., Huang, Y., Zhou, H., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.05.007 · Cited by 253
Association of Fecal and Plasma Levels of Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Patients With Parkinson Disease
Chen, S.-J., Chen, C.-C., Liao, H.-Y., Lin, Y.-T., Wu, Y.-W., Liou, J.-M., Wu, M.-S., Kuo, C.-H., & Lin, C.-H. (2022) · Neurology · doi:10.1212/wnl.0000000000013225 · Cited by 269
Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study
Minato, T., Maeda, T., Fujisawa, Y., Tsuji, H., Nomoto, K., Ohno, K., & Hirayama, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187307 · Cited by 248
The intestinal barrier in disorders of the central nervous system
Pellegrini, C., Fornai, M., D'Antongiovanni, V., Antonioli, L., Bernardini, N., & Derkinderen, P. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00241-2 · Cited by 239
The Microbiome as a Modifier of Neurodegenerative Disease Risk
Fang, P., Kazmi, S. A., Jameson, K. G., & Hsiao, E. Y. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.008 · Cited by 226
Microglia affect α-synuclein cell-to-cell transfer in a mouse model of Parkinson’s disease
George, S., Rey, N. L., Tyson, T., Esquibel, C., Meyerdirk, L., Schulz, E., Pierce, S., Burmeister, A. R., Madaj, Z., Steiner, J. A., et al. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0335-3 · Cited by 229
Desulfovibrio Bacteria Are Associated With Parkinson’s Disease
Murros, K. E., Huynh, V. A., Takala, T. M., & Saris, P. E. J. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.652617 · Cited by 218
Microbiota-gut-brain signalling in Parkinson's disease: Implications for non-motor symptoms
Felice, V. D., Quigley, E. M., Sullivan, A. M., O'Keeffe, G. W., & O'Mahony, S. M. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.03.012 · Cited by 205
Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology
Manfredsson, F. P., Luk, K. C., Benskey, M. J., Gezer, A., Garcia, J., Kuhn, N. C., Sandoval, I. M., Patterson, J. R., O'Mara, A., Yonkers, R., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.01.008 · Cited by 199
Self-citation
Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease
Houser, M. C., Chang, J., Factor, S. A., Molho, E., Zabetian, C. P., Hill‐Burns, E. M., Payami, H., Hertzberg, V., & Tansey, M. G. (2018) · Movement Disorders · doi:10.1002/mds.27326 · Cited by 204
Gut–brain axis and the spread of α‐synuclein pathology: Vagal highway or dead end?
Breen, D. P., Halliday, G. M., & Lang, A. E. (2019) · Movement Disorders · doi:10.1002/mds.27556 · Cited by 193
Altered gut microbiome in parkinson’s disease and the influence of lipopolysaccharide in a human α-synuclein over-expressing mouse model
Gorecki, A. M., Preskey, L., Bakeberg, M. C., Kenna, J. E., Gildenhuys, C., MacDougall, G., Dunlop, S. A., Mastaglia, F. L., Akkari, P. A., Koengten, F., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00839 · Cited by 184
Gut microbiome dysbiosis across early Parkinson’s disease, REM sleep behavior disorder and their first-degree relatives
Huang, B., Chau, S. W. H., Liu, Y., Chan, J. W. Y., Wang, J., Ma, S. L., Zhang, J., Chan, P. K. S., Yeoh, Y. K., Chen, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38248-4 · Cited by 187
Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease
Zhu, M., Liu, X., Ye, Y., Yan, X., Cheng, Y., Zhao, L., Chen, F., & Ling, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.937555 · Cited by 177
Parkinson’s Disease and the Gastrointestinal Microbiome
Lubomski, M., Tan, A. H., Lim, S.-Y., Holmes, A. J., Davis, R. L., & Sue, C. M. (2020) · Journal of Neurology · doi:10.1007/s00415-019-09320-1 · Cited by 172
Oral administration of Proteus mirabilis damages dopaminergic neurons and motor functions in mice
Choi, J. G., Kim, N., Ju, I. G., Eo, H., Lim, S.-M., Jang, S.-E., Kim, D.-H., & Oh, M. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19646-x · Cited by 170
Synaptic failure and α‐synuclein
Calò, L., Węgrzynowicz, M., Santivañez‐Perez, J., & Spillantini, M. G. (2016) · Movement Disorders · doi:10.1002/mds.26479 · Cited by 179
The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease
Yang, D., Zhao, D., Ali Shah, S. Z., Wu, W., Lai, M., Zhang, X., Li, J., Guan, Z., Zhao, H., Li, W., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01155 · Cited by 162
Preventing Parkinson’s Disease: An Environmental Agenda
Miranda, B. R. D., Goldman, S. M., Miller, G. W., Greenamyre, J. T., & Dorsey, E. R. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212922 · Cited by 171
Parkinson’s Disease and Gut Microbiota
Hirayama, M., & Ohno, K. (2021) · Annals of Nutrition and Metabolism · doi:10.1159/000518147 · Cited by 158
Gut Microbiota Dysfunction as Reliable Non-invasive Early Diagnostic Biomarkers in the Pathophysiology of Parkinson's Disease: A Critical Review
Nair, A. T., Ramachandran, V., Joghee, N. M., Shanish Antony, A., & Ramalingam, G. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm17105 · Cited by 164
Role of Endogenous Lipopolysaccharides in Neurological Disorders
Kalyan, M., Hediyal, T. A., Sonali, S., Vichitra, C., Sunanda, T., Praveenraj, S. S., Ray, B., Gorantla, V. R., Rungratanawanich, W., Mahalakshmi, A. M., et al. (2022) · Cells · doi:10.3390/cells11244038 · Cited by 172
Parkinson’s Disease: The Emerging Role of Gut Dysbiosis, Antibiotics, Probiotics, and Fecal Microbiota Transplantation
Dutta, S., Verma, S., Jain, V., Surapaneni, B. K., Vinayek, R., Phillips, L. E., & Nair, P. P. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19044 · Cited by 150
Effect of Parkinson’s Disease and Related Medications on the Composition of the Fecal Bacterial Microbiota
Weis, S., Schwiertz, A., Unger, M. M., Becker, A., Faßbender, K., Ratering, S., Kohl, M., Schnell, S., Schäfer, K.-H., & Egert, M. (2019) · npj Parkinson s Disease · doi:10.1038/s41531-019-0100-x · Cited by 145
Exposure to bacterial endotoxin generates a distinct strain of α-synuclein fibril
Kim, C., Lv, G., Lee, J. S., Jung, B. C., Masuda-Suzukake, M., Hong, C.-S., Valera, E., Lee, H.-J., Paik, S. R., Hasegawa, M., et al. (2016) · Scientific Reports · doi:10.1038/srep30891 · Cited by 138
Fecal Calprotectin as a Marker of the Gut Immune System Activation Is Elevated in Parkinson’s Disease
Mulak, A., Koszewicz, M., Panek-Jeziorna, M., Koziorowska-Gawron, E., & Budrewicz, S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00992 · Cited by 110
Enteric glial cells: New players in Parkinson's disease?
Clairembault, T., Leclair‐Visonneau, L., Neunlist, M., & Derkinderen, P. (2015) · Movement Disorders · doi:10.1002/mds.25979 · Cited by 117
In vivo gastric detection of α-synuclein inclusions in Parkinson's disease
Sánchez‐Ferro, Á., Rábano, A., Catalán, M. J., Rodríguez‐Valcárcel, F. C., Díez, S. F., Herreros‐Rodríguez, J., García‐Cobos, E., Álvarez‐Santullano, M. M., López‐Manzanares, L., Mosqueira, A. J., et al. (2015) · Movement Disorders · doi:10.1002/mds.25988 · Cited by 123
The Gut-Brain Axis: Two Ways Signaling in Parkinson’s Disease
Dogra, N., Mani, R. J., & Katare, D. P. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01066-7 · Cited by 121
Gut Vibes in Parkinson's Disease: The Microbiota‐Gut‐Brain Axis
Bullich‐Vilarrubias, C., Keshavarzian, A., Garssen, J., Kraneveld, A. D., & Perez‐Pardo, P. (2019) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12840 · Cited by 120
Self-citation
Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease
Deng, I. B., Corrigan, F., Zhai, G., Zhou, X., & Bobrovskaya, L. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100060 · Cited by 129
Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment
Salim, S., Ahmad, F. A., Banu, A., & Mohammad, F. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.10.013 · Cited by 124
Altered Gut Microbiota in Parkinson’s Disease Patients/Healthy Spouses and Its Association with Clinical Features
Zhang, F., Yue, L., Fang, X., Wang, G., Li, C., Sun, X., Jia, X., Yang, J., Song, J., Zhang, Y., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.10.034 · Cited by 111
No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases
Kell, D. B., & Pretorius, E. (2018) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12407 · Cited by 117
The Intestinal Barrier in Parkinson’s Disease: Current State of Knowledge
van IJzendoorn, S. C. D., & Derkinderen, P. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191707 · Cited by 97
Genome-wide screen identifies curli amyloid fibril as a bacterial component promoting host neurodegeneration
Wang, C., Lau, C. Y., Ma, F., & Zheng, C. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2106504118 · Cited by 106
TLR2 and TLR4 in Parkinson’s disease pathogenesis: The environment takes a toll on the gut
Gorecki, A. M., Anyaegbu, C. C., & Anderton, R. S. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00271-0 · Cited by 103
Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease
Chiang, H., & Lin, C. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.18067 · Cited by 107
Gut bacterial composition in a mouse model of Parkinson’s disease
Perez-Pardo, P., Dodiya, H. B., Engen, P. A., Naqib, A., Forsyth, C. B., Green, S. J., Garssen, J., Keshavarzian, A., & Kraneveld, A. D. (2018) · Beneficial Microbes · doi:10.3920/bm2017.0202 · Cited by 102
Self-citation
Potential roles of gut microbiota and microbial metabolites in Parkinson’s disease
Zheng, S.-Y., Li, H.-X., Xu, R.-C., Miao, W.-T., Dai, M.-Y., Ding, S.-T., & Liu, H.-D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101347 · Cited by 101
Probiotics for Parkinson's disease: Current evidence and future directions
Tan, A. H., Hor, J. W., Chong, C. W., & Lim, S. (2020) · JGH Open · doi:10.1002/jgh3.12450 · Cited by 103
Role of Akkermansia in Human Diseases: From Causation to Therapeutic Properties
Pellegrino, A., Coppola, G., Santopaolo, F., Gasbarrini, A., & Ponziani, F. R. (2023) · Nutrients · doi:10.3390/nu15081815 · Cited by 107
Association between inflammatory bowel diseases and Parkinson's disease: systematic review and meta-analysis
Zhu, Y., Yuan, M., Zhu, Y., Yang, F., Chen, W., Xu, Z.-Z., Xiang, Z.-B., & Xu, R.-S. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.317981 · Cited by 95
Antibiotic Exposure and Risk of Parkinson's Disease in Finland: A Nationwide Case‐Control Study
Mertsalmi, T. H., Pekkonen, E., & Scheperjans, F. (2020) · Movement Disorders · doi:10.1002/mds.27924 · Cited by 88
Oral P. gingivalis impairs gut permeability and mediates immune responses associated with neurodegeneration in LRRK2 R1441G mice
Feng, Y.-K., Wu, Q.-L., Peng, Y.-W., Liang, F.-Y., You, H.-J., Feng, Y.-W., Li, G., Li, X.-J., Liu, S.-H., Li, Y.-C., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02027-5 · Cited by 87
Quantification of hydrogen production by intestinal bacteria that are specifically dysregulated in Parkinson's disease
Suzuki, A., Ito, M., Hamaguchi, T., Mori, H., Takeda, Y., Baba, R., Watanabe, T., Kurokawa, K., Asakawa, S., Hirayama, M., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208313 · Cited by 93
Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis
Fang, X. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2015.1096271 · Cited by 84
The gut-brain axis and Parkinson disease: Clinical and pathogenetic relevance
Menozzi, E., Macnaughtan, J., & Schapira, A. H. V. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.1890330 · Cited by 81
Animal models of Parkinson’s disease: a guide to selecting the optimal model for your research
Lama, J., Buhidma, Y., Fletcher, E. J. R., & Duty, S. (2021) · Neuronal Signaling · doi:10.1042/ns20210026 · Cited by 93
Parkinson's Disease Is Associated with Impaired Gut–Blood Barrier for Short‐Chain Fatty Acids
Yang, X., Ai, P., He, X., Mo, C., Zhang, Y., Xu, S., Lai, Y., Qian, Y., & Xiao, Q. (2022) · Movement Disorders · doi:10.1002/mds.29063 · Cited by 82
The Endotoxin Hypothesis of Parkinson's Disease
Brown, G. C., Camacho, M., & Williams‐Gray, C. H. (2023) · Movement Disorders · doi:10.1002/mds.29432 · Cited by 85
Microbiome, Parkinson’s Disease and Molecular Mimicry
Miraglia, F., & Colla, E. (2019) · Cells · doi:10.3390/cells8030222 · Cited by 84
Preventing Bacterial Translocation in Patients with Leaky Gut Syndrome: Nutrition and Pharmacological Treatment Options
Twardowska, A., Makaro, A., Binienda, A., Fichna, J., & Sałaga, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063204 · Cited by 84
Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS)
Bester, J., Soma, P., Kell, D. B., & Pretorius, E. (2015) · Oncotarget · doi:10.18632/oncotarget.6074 · Cited by 77
Neurogenic and anti-inflammatory effects of probiotics in Parkinson’s disease: A systematic review of preclinical and clinical evidence
Leta, V., Chaudhuri, К. R., Milner, O., Chung‐Faye, G., Metta, V., Pariante, C. M., & Borsini, A. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.07.026 · Cited by 79
Animal models of brain-first and body-first Parkinson's disease
Berge, N. V. D., & Ulusoy, A. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105599 · Cited by 80
Intestinal Inflammation and Parkinson’s Disease
Li, Y., Chen, Y., Jiang, L., Zhang, J., Tong, X., Chen, D., & Le, W. (2021) · Aging and Disease · doi:10.14336/ad.2021.0418 · Cited by 75
Dietary Carbohydrates and Lipids in the Pathogenesis of Leaky Gut Syndrome: An Overview
Binienda, A., Twardowska, A., Makaro, A., & Sałaga, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218368 · Cited by 76
Gut microenvironmental changes as a potential trigger in Parkinson’s disease through the gut–brain axis
Chen, S., & Lin, C. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00839-6 · Cited by 85
Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review)
Lei, Q., Wu, T., Wu, J., Hu, X., Guan, Y., Wang, Y., Yan, J., & Shi, G. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12374 · Cited by 74
The Prion Hypothesis of Parkinson’s Disease
Chu, Y., & Kordower, J. H. (2015) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0549-x · Cited by 74
Self-citation
Parkinson's disease: Microglial/macrophage-induced immunoexcitotoxicity as a central mechanism of neurodegeneration
Blaylock, R. L. (2017) · Surgical Neurology International · doi:10.4103/sni.sni_441_16 · Cited by 67
Host-microbiome interactions: the aryl hydrocarbon receptor and the central nervous system
Lee, H. U., McPherson, Z. E., Tan, B., Korecka, A., & Pettersson, S. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1486-0 · Cited by 65
Gastrointestinal Immunity and Alpha-Synuclein
Barbut, D., Stolzenberg, E. D., & ZASLOFF, M. A. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191702 · Cited by 66
Intestinal epithelial barrier and neuromuscular compartment in health and disease
D’Antongiovanni, V., Pellegrini, C., Fornai, M., Colucci, R., Blandizzi, C., Antonioli, L., & Bernardini, N. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i14.1564 · Cited by 63
Dysregulation of the Gut-Brain Axis, Dysbiosis and Influence of Numerous Factors on Gut Microbiota Associated Parkinson's Disease
Kaur, G., Behl, T., BUNGAU, S. G., Kumar, A., Uddin, M. S., Mehta, V., Zengin, G., Mathew, B., Shah, M. A., & Arora, S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200606233050 · Cited by 57
Enteric Glia at the Crossroads between Intestinal Immune System and Epithelial Barrier: Implications for Parkinson Disease
Benvenuti, L., D’Antongiovanni, V., Pellegrini, C., Antonioli, L., Bernardini, N., Blandizzi, C., & Fornai, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239199 · Cited by 56
GPER1-mediated immunomodulation and neuroprotection in the myenteric plexus of a mouse model of Parkinson's disease
Côté, M., Bourque, M., Poirier, A.-A., Aubé, B., Morissette, M., Paolo, T. D., & Soulet, D. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.05.017 · Cited by 58
Association of small intestinal bacterial overgrowth with Parkinson’s disease: a systematic review and meta-analysis
Li, X., Feng, X., Jiang, Z., & Jiang, Z. (2021) · Gut Pathogens · doi:10.1186/s13099-021-00420-w · Cited by 54
Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease
Zheng, T., & Zhang, Z. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105094 · Cited by 57
Influence of commensal microbiota on the enteric nervous system and its role in neurodegenerative diseases
Endres, K., & Schäfer, K.-H. (2018) · Journal of Innate Immunity · doi:10.1159/000488629 · Cited by 52
Microbes Tickling Your Tummy: the Importance of the Gut-Brain Axis in Parkinson’s Disease
Perez‐Pardo, P., Hartog, M., Garssen, J., & Kraneveld, A. D. (2017) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-017-0129-2 · Cited by 53
BDNF and Netrin-1 repression by C/EBPβ in the gut triggers Parkinson’s disease pathologies, associated with constipation and motor dysfunctions
Ahn, E. H., Kang, S. S., Liu, X., Cao, X., Choi, S. Y., Musazzi, L., Mehlen, P., & Ye, K. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101905 · Cited by 51
Inflammasome Activation in Parkinson’s Disease
Jewell, S. L., Herath, A. M., & Gordon, R. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223338 · Cited by 53
Gastrointestinal disorders in Parkinson’s disease and other Lewy body diseases
Hirayama, M., Nishiwaki, H., Hamaguchi, T., & Ohno, K. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00511-2 · Cited by 51
Targeting selective autophagy and beyond: From underlying mechanisms to potential therapies
Ma, W., Lü, Y., Jin, X., Lin, N., Zhang, L., & Song, Y. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.05.009 · Cited by 52
Clinical Phenotypes of Parkinson’s Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes
Vascellari, S., Melis, M., Palmas, V., Pisanu, S., Serra, A., Perra, D., Santoru, M. L., Oppo, V., Cusano, R., Uva, P., et al. (2021) · Biomolecules · doi:10.3390/biom11020144 · Cited by 52
Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease
Pretorius, E., Pagé, M., Mbotwe, S., & Kell, D. B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192121 · Cited by 47
What Is the Evidence that Parkinson’s Disease Is a Prion Disorder, Which Originates in the Gut?
Kujawska, M., & Jodynis‐Liebert, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113573 · Cited by 48
Composition of intestinal flora affects the risk relationship between Alzheimer's disease/Parkinson's disease and cancer
Hang, Z., Lei, T., Zeng, Z., Cai, S., Bi, W., & Du, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112343 · Cited by 45
Gastrointestinal Dysfunction in Parkinson’s Disease: Current and Potential Therapeutics
Han, M. N., Finkelstein, D. I., McQuade, R. M., & Diwakarla, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020144 · Cited by 50
A nutritional approach to microbiota in Parkinson’s disease
Uyar, G. Ö., & Yıldıran, H. (2019) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.19-002 · Cited by 49
Reducing the Amyloidogenicity of Functional Amyloid Protein FapC Increases Its Ability To Inhibit α-Synuclein Fibrillation
Christensen, L. F. B., Jensen, K. F., Nielsen, J., Vad, B. S., Christiansen, G., & Otzen, D. E. (2019) · ACS Omega · doi:10.1021/acsomega.8b03590 · Cited by 45
Modification of the gut microbiome to combat neurodegeneration
Sasmita, A. O. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0005 · Cited by 50
Exploring Human-Genome Gut-Microbiome Interaction in Parkinson’s Disease
Wallen, Z. D., Stone, W. J., Factor, S. A., Molho, E., Zabetian, C. P., Standaert, D. G., & Payami, H. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00218-2 · Cited by 41

Authors: Kelly, L. P., Carvey, P. M., Keshavarzian, A., Shannon, K. M., Shaikh, M., Bakay, R. A. E., & Kordower, J. H.
Affiliations: Rush University (US)
Utrecht University (NL)
Corresponding author: Kordower, Jeffrey H.
ORCID: Keshavarzian, Ali
Shannon, Kathleen M.
Kordower, Jeffrey H.
Venue: Movement Disorders
Publisher: Wiley
Published: 2013-11-04
Volume: 29
Issue: 8
Pages: 999-1009
ISSN: 0885-3185 (ISSN-L)
1531-8257
DOI: 10.1002/mds.25736
PMC: PMC4050039
OpenAlex: W2108108635
Cited by: 308
References: 61
Citations by year: 2026: 11 · 2025: 21 · 2024: 28 · 2023: 55 · 2022: 34 · 2021: 54 · 2020: 29 · 2019: 24 · 2018: 18 · 2017: 13 · 2016: 6 · 2015: 9 · 2014: 6
FWCI: 4.44
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Movement Disorders (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of Neurological Disorders and Stroke (R01NS055143)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, intestinal permeability, alpha-synuclein, lipopolysaccharide, gastrointestinal dysfunction, nigrostriatal degeneration, tyrosine hydroxylase, disease biomarkers, mouse model, gut-brain axis
MeSH terms: Animals, Brain, Chromatography, Gas, Colon, Disease Models, Animal, Gastrointestinal Agents, Male, Mice, Inbred C57BL, Parkinson Disease, Permeability, Polysaccharides, Severity of Illness Index, Time Factors, Tyrosine 3-Monooxygenase, Vagus Nerve, Linear Models, Disease Progression, Mice, alpha-Synuclein

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks